Plain-English translation of NCT07021313 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atrial Fibrillation research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Atrial fibrillation is an irregular heart rhythm that doctors often treat with a procedure called pulmonary vein isolation, which uses energy to scar heart tissue and restore normal rhythm. This trial is testing whether delivering more ablation applications during the FARAPULSE procedure — a newer technology that uses pulsed energy — can make the treatment more durable and prevent the heart rhythm problem from returning.
Current ablation methods sometimes don't last long-term because the treated heart tissue can reconnect over time, causing the irregular rhythm to return. This trial wants to see if giving more targeted applications of the new treatment during the initial procedure can create better, longer-lasting results.
You likely qualify if…
You likely don't qualify if…
You will undergo the standard ablation procedure at a participating center, where doctors will use the FARAPULSE system to perform pulmonary vein isolation. Half of participants will receive the standard number of ablation applications (8 total), while the other half will receive extra applications (12 total) in different shapes to create better tissue scarring. After the procedure, you will be monitored for 18 months to track how often your heart rhythm problem returns.
AI-generated summary from trial data · Jul 2, 2026 · Not medical advice
Netherlands